Biosimilar Boom May be on the Horizon, Potentially Saving Patients Billions
Biosimilars, biologic generics, hold substantial promise in expanding access to lifesaving biologics, but growth has taken a while to ramp up. With 100 biosimilars currently in the pipeline, the industry may be set up for rapid growth in the next two years. With the potential influx of new biosimilars that are significantly cheaper than their reference drugs, patients could collectively save $100 billion in the next 5 years.
Delivering Real World Data-Driven Insights: An Executive Interview with Wendy Shusko and Jason Drenning
Delivering Real World Data-Driven Insights:An Executive Interview with Wendy Shusko and Jason Drenning Wendy Shusko, President and CEO and Jason [...]
ISPOR General Business Meeting to Take Place on May 26th
ISPOR will hold a virtual General Business Meeting on May 26th from 9:00 AM to 9:45 AM EDT. The session [...]
National AHIP Conference Provides Information on Drug Pricing and Health Policy Outlook
The national AHIP (America’s Health Insurance Plans) conference took place earlier this week. It provided important information regarding prescription drug [...]
NICE Talking to You: The Value of Early Scientific Advice
Starting in 2009, NICE became a pioneer among health technology assessment (HTA) agencies by offering the opportunity for early scientific [...]
Racial Biases Persist in Widely-used Analytics Software
According to a recent article published by Casey Ross of Stat News, infusion of bias into decisions about who should [...]
Educating the Next Leaders in Applied HEOR: Jefferson’s Unique Approach
Online education for the working professional is experiencing exponential growth. In the field of Health Economics and Outcomes Research (HEOR), [...]
The Influence of HEOR Data on Payer Formulary Coverage
A recent study presented by ISPOR demonstrated how HEOR data positively influenced changes to US payer formulary coverage. Investigators surveyed [...]
Cost-Sharing Waivers for COVID-19 Treatment Are Expiring
Cost-sharing waivers for COVID-19 treatment are due to expire in the upcoming months. Approximately 88% in individual and fully insured [...]
Payer Contact in a “Contactless” World: Achieving Early Engagement
The COVID-19 pandemic has prompted life sciences organizations to quickly pivot their payer strategic approach and tactical implementation. Engaging payers [...]
Kamala Harris Is No Friend to Pharma
Vice presidential nominee Kamala Harris is not exactly the centrist the media are making her out to be—especially when it [...]
Lilly + Prime Therapeutics Push the Envelope on Next Generation Value-based Agreements
Lilly has partnered with Prime Therapeutics to explore how value-based arrangements (VBA’s) can be used to improve patient outcomes while [...]
OM1 Insights: How We Use AI to Find Rare Disease Patients
"Correctly identifying a patient with a rare disease can be like looking for a needle in a haystack", according to [...]
Real-world Evidence Put to the Test: Medicare’s New Codes for Remdesivir
The Centers for Medicare & Medicaid Services (CMS) has created new ICD-10-PCS procedure reimbursement codes to facilitate the generation of [...]
COVID-19 Vaccine Pricing: Are the Manufacturers Signaling their Intent?
The Wall Street Journal is reporting that vaccine manufacturers are signaling the price for coronavirus vaccines, with prices ranging from [...]
Gilead Pricing of Remdesivir is “Immoral”, Says Pennsylvania’s Treasurer
Joe Torsella, Pennsylvania's elected treasurer, has come out swinging, calling Gilead Sciences "immoral" for their efforts to wring profit out [...]
Invoke a 1980’s Law to Lower Cost of Remdesivir for COVID-19, says 31 State Attorneys General
A coalition of attorneys general (AG) have requested the U.S. Department of Health and Human Services to invoke a federal [...]
Trump’s “Buy American” Executive Order Could Raise Drug Prices
Tensions escalate with pharma as President Trump signs an executive order (EO) today directing the federal government to buy certain [...]
What is the Global Access Impact of COVID-19? DRG and Context Matters Weighs In
Mike Ward, Global Head of Thought Leadership at Decision Resources Group talks with Steve Edgar of DRG Global Market Access [...]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from [...]
Trump v. Pharma: a “Kinda Sorta” War
Politico summarizes Trump's "kinda sorta" war with pharma, kicked off last week with presidential tweets about "nasty" drug ads that [...]
Not interested: Pharma execs refuse White House meeting over drug pricing executive orders
Trump's recent executive orders linking drug prices in Medicare to lower prices abroad caused a significant rift with the pharma [...]
Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward
In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing [...]
Dread Expressed by Public Health Experts on Hurried FDA Signoff on COVID-19 Vaccine
Eighty-nine sites are enrolling patients in the landmark Phase 3 trial for Moderna Therapeutics vaccine kicked off on Monday, July [...]
New Platform for Affordable Genomic Cancer Profiling Launched
A next-generation sequencing reference laboratory will use artificial intelligence (AI) to advance precision medicine to determine genomic signatures, first for [...]
